Functional variation of HIV-1 Rev Response Element in a longitudinally studied cohort

Journal of Medical Virology

Volumn 75, Issue 3, 2005, Pages 367-373

  Phuphuakrat, Angsana ^a   Paris, Robert M ^b   Nittayaphan, Sorachai ^b   Louisirirotchanakul, Suda ^a   Auewarakul, Prasert ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

Author keywords

CD4+ count; Disease progression; RRE

Indexed keywords

CD4 ANTIGEN; CIS ACTING ELEMENT; REV RESPONSE ELEMENT; UNCLASSIFIED DRUG;

ARTICLE; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MALE; NONHUMAN; STRUCTURE ANALYSIS; VIRUS ISOLATION; VIRUS PATHOGENESIS;

ADULT; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; DNA, VIRAL; FEMALE; GENES, ENV; GENETIC HETEROGENEITY; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 12944265407     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20279     Document Type: Article

References (32)

1. Arrigo SJ, Chen IS. 1991. Rev is necessary for translation but not cytoplasmic accumulation of HIV-1 vif, vpr, and env/vpu 2 RNAs. Genes Dev 5:808-819.
2. Arrigo SJ, Weitsman S, Rosenblatt JD, Chen IS. 1989. Analysis of rev gene function on human immunodeficiency virus type 1 replication in lymphoid cells by using a quantitative polymerase chain reaction method. J Virol 63:4875-4881.
3. Cecilia D, Kulkarni SS, Tripathy SP, Gangakhedkar RR, Paranjape RS, Gadkari DA. 2000. Absence of coreceptor switch with disease progression in human immunodeficiency virus infections in India. Virology 271:253-258.
4. Comar M, Simonelli C, Zanussi S, Paoli P, Vaccher E, Tirelli U, Giacca M. 1997. Dynamics of HIV-1 mRNA expression in patients with long-term nonprogressive HIV-1 infection. J Clin Invest 100:893-903.
5. Connor RI, Sheridan KE, Lai C, Zhang L, Ho DD. 1996. Characterization of the functional properties of env genes from long-term survivors of human immunodeficiency virus type 1 infection. J Virol 70:5306-5311.
6. de Roda Husman AM, van Rij RP, Blaak H, Broersen S, Schuitemaker H. 1999. Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression. J Infect Dis 180:1106-1115.
7. Deacon NJ, Tsykin A, Solomon A, Smith K, Ludford-Menting M, Hooker DJ, McPhee DA, Greenway AL, Ellett A, Chatfield C, et al. 1995. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270:988-991.
8. Felber BK, Hadzopoulou-Cladaras M, Cladaras C, Copeland T, Pavlakis GN. 1989. rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA. Proc Natl Acad Sci USA 86:1495-1499.
9. + T-cell number decline in human immunodeficiency virus type 1-infected individuals. J Virol 69:2092-2100.
10. Hammarskjold ML, Heimer J, Hammarskjold B, Sangwan I, Albert L, Rekosh D. 1989. Regulation of human immunodeficiency virus env expression by the rev gene product. J Virol 63:1959-1966.
11. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, Rang S, Ceradini D, Jin Z, Yazdanbakhsh K, Kunstman K, Erickson D, Dragon E, Landau NR, Phair J, Ho DD, Koup RA. 1996. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 2:1240-1243.
12. Huang Y, Zhang L, Ho DD. 1998. Characterization of gag and pol sequences from long-term survivors of human immunodeficiency virus type 1 infection. Virology 240:36-49.
13. Iversen AK, Shpaer EG, Rodrigo AG, Hirsch MS, Walker BD, Sheppard HW, Merigan TC, Mullins JI. 1995. Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected asymptomatic individual. J Virol 69:5743-5753.
14. Kilmarx PH, Limpakarnjanarat K, Kaewkungwal J, Srismith R, Saisorn S, Uthaivoravit W, Young NL, Mastro TD. 2000. Disease progression and survival with human immunodeficiency virus type 1 subtype E infection among female sex workers in Thailand. J Infect Dis 181:1598-1606.
15. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. 1995. Brief report: Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 332:228-232.
16. Li J, Tang H, Mullen TM, Westberg C, Reddy TR, Rose DW, Wong-Staal F. 1999. A role for RNA helicase A in post-transcriptional regulation of HIV type 1. Proc Natl Acad Sci USA 96:709-714.
17. Louisirirotchanakul S, Phanknilrat P, Poonarknguen R, Auewarakul P, Wasi C. 2004. Multiplex PCR-Restriction length polymorphism assay for 3 hot genetic polymorphisms associated with HIV-1 pathogenesis. J Med Tech Assoc Thailand 31:776-786.
18. Malim MH, Hauber J, Le SY, Maizel JV, Cullen BR. 1989. The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 338:254-257.
19. Michael NL. 1999. Host genetic influences on HIV-1 pathogenesis. Curr Opin Immunol 11:466-474.
20. Michael NL, Mo T, Merzouki A, O'Shaughnessy M, Oster C, Burke DS, Redfield RR, Birx DL, Cassol SA. 1995. Human immunodeficiency virus type 1 cellular RNA load and splicing patterns predict disease progression in a longitudinally studied cohort. J Virol 69:1868-1877.
21. Morris L, Cilliers T, Bredell H, Phoswa M, Martin DJ. 2001. CCR5 is the major coreceptor used by HIV-1 subtype C isolates from patients with active tuberculosis. AIDS Res Hum Retroviruses 17:697-701.
22. Neumann M, Harrison J, Saltarelli M, Hadziyannis E, Erfle V, Felber BK, Pavlakis GN. 1994. Splicing variability in HIV type 1 revealed by quantitative RNA polymerase chain reaction. AIDS Res Hum Retroviruses 10:1531-1542.
23. Phuphuakrat A, Auewarakul P. 2003. Heterogeneity of HIV-1 Rev response element. AIDS Res Hum Retroviruses 19:569-574.
24. Ping LH, Nelson JA, Hoffman IF, Schock J, Lamers SL, Goodman M, Vernazza P, Kazembe P, Maida M, Zimba D, Goodenow MM, Eron JJ Jr, Fiscus SA, Cohen MS, Swanstrom R. 1999. Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: Underrepresentation of X4 variants. J Virol 73:6271-6281.
25. Powell DM, Amaral MC, Wu JY, Maniatis T, Greene WC. 1997. HIV Rev-dependent binding of SF2/ASF to the Rev response element: Possible role in Rev-mediated inhibition of HIV RNA splicing. Proc Natl Acad Sci USA 94:973-978.
26. Reddy TR, Xu W, Mau JK, Goodwin CD, Suhasini M, Tang H, Frimpong K, Rose DW, Wong-Staal F. 1999. Inhibition of HIV replication by dominant negative mutants of Sam68, a functional homolog of HIV-1 Rev. Nat Med 5:635-642.
27. Schwartz S, Felber BK, Pavlakis GN. 1992. Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein. J Virol 66:150-159.
28. Theodorou I, Capoulade C, Combadiere C, Debre P. 2003. Genetic control of HIV disease. Trends Microbiol 11:392-397.
29. Xu Y, Reddy TR, Fischer WH, Wong-Staal F. 1996. A Novel hnRNP Specifically Interacts with HIV-1 RRE RNA. J Biomed Sci 3:82-91.
30. Yamada T, Iwamoto A. 2000. Comparison of proviral accessory genes between long-term nonprogressors and progressors of human immunodeficiency virus type 1 infection. Arch Virol 145:1021-1027.
31. Zhang L, Huang Y, Yuan H, Chen BK, Ip J, Ho DD. 1997a. Genotypic and phenotypic characterization of long terminal repeat sequences from long-term survivors of human immunodeficiency virus type 1 infection. J Virol 71:5608-5613.
32. Zhang L, Huang Y, Yuan H, Tuttleton S, Ho DD. 1997b. Genetic characterization of vif, vpr, and vpu sequences from long-term survivors of human immunodeficiency virus type 1 infection. Virology 228:340-349.